ProCE Banner Activity

CONKO-007: Chemoradiotherapy vs Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer

Slideset Download
Conference Coverage
Addition of radiotherapy to chemotherapy significantly improved the R0 resection rate specifically in patients who underwent surgery after chemoradiotherapy or chemotherapy alone but not in the overall population of patients with unresectable locally advanced pancreatic cancer.

Released: June 10, 2022

Expiration: June 09, 2023

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab